ABOUT US
A global leader in innovative genomic
technology and diagnostic tests.
What’s new at Agendia?
Get the latest updates on our company and products, as well as new developments in genomic science.
News
In the News
News
Media Releases
AJCC Confirms MammaPrint’s Clinical Utility for Treatment Decisions and Staging in Recent 8th Edition Breast Chapter Update
Update clarifies that the patient and clinician may choose any genomic profile or multigene panel based on available clinical evidence at the time of treatment In line with recent publications from NEJM and ASCO, the Read More
New Study Published in JAMA Oncology Shows MammaPrint Changed Breast Cancer Treatment Decisions in 3 out of 4 Cases where Guidance was Unclear with the 21-Gene Assay
Prospective PROMIS trial showed no correlation between the two tests highlighting potential under-and over-treatment risks throughout the 21-gene assay’s intermediate range Physicians changed their treatment decisions in approximately 34% of all cases and in 76% Read More
Breast Cancer is the Most Feared Cancer Among Women in Germany, Although Less than Half are Aware of the Benefits of Genomic Testing
KANTAR survey: Only 40% of breast cancer patients know the benefits of genomic testing IRVINE, CA and AMSTERDAM, 9 October 2017 – Breast cancer is the most feared type of cancer among women in Germany, Read More
Breast Cancer – Let’s Make It Personal: Agendia Supports Breast Cancer Awareness Month with International Program of Activities
Flash Mob for Breast Cancer Empowerment, in partnership with the Tigerlily Foundation, takes place at the Lincoln Memorial in Washington, DC on Saturday 14 October International events including support of Susan G. Komen Race for Read More
